Video
Dr. Neal Shore on the future of darolutamide in prostate cancer
Author(s):
Darolutamide is currently approved for the treatment of patients with nonmetastatic castration-resistant prostate cancer.
Video Player is loading.
Neal D. Shore, MD, medical director of the Carolina Urologic Research Center, highlights the next steps for darolutamide (Nubeqa) in prostate cancer. The FDA approved the androgen receptor pathway inhibitor in July 2019 for the treatment of patients with nonmetastatic castration-resistant prostate cancer, based on findings from the phase 3 ARAMIS trial.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Related Videos
Jad Chahoud, MD, on the phase 1b STELLAR-002 trial in ccRCC
Jens Bedke, MD, on efficacy of EV plus pembrolizumab across subgroups in la/mUC
Professor Dickon Hayne shares data on mitomycin plus BCG in high-risk NMIBC
Thomas Powles, MBBS, MRCP, MD, on efficacy of sasanlimab plus BCG in BCG-naïve NMIBC
Andrew Armstrong, MD, shares 5-year data on enzalutamide plus ADT in mHSPC
Professor Dickon Hayne on bladder cancer data to watch for at ASCO 2025
Andrew Armstrong, MD, previews key prostate cancer data at ASCO 2025
5 key trial insights from AUA 2025
Shreyas Joshi, MD, recaps AUA session on chemotherapy vs novel NMIBC options
Shay Rajavel, MS3, on CO2 gas embolism during single-port partial nephrectomy
Related Content
